Sherbrooke Park Advisers LLC Has $420,000 Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sherbrooke Park Advisers LLC lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 36.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,017 shares of the company's stock after selling 585 shares during the quarter. Sherbrooke Park Advisers LLC's holdings in IDEXX Laboratories were worth $420,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Hurley Capital LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $29,000. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $30,000. Retirement Wealth Solutions LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $31,000. Colonial Trust Co SC boosted its stake in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after purchasing an additional 39 shares in the last quarter. Finally, Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $38,000. Institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on IDXX shares. Stifel Nicolaus boosted their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a report on Monday. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Bank of America lifted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Morgan Stanley lifted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Finally, Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $536.00.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded down $4.52 during midday trading on Tuesday, reaching $517.16. The company had a trading volume of 606,894 shares, compared to its average volume of 649,203. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $41.59 billion, a price-to-earnings ratio of 48.47, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. The stock has a fifty day simple moving average of $435.69 and a 200 day simple moving average of $432.77. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.60.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. During the same quarter in the prior year, the business posted $2.71 EPS. The firm's quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.